ID   A-375
AC   CVCL_0132
SY   A 375; A375; A375-MEL; A375-mel; A375mel
DR   BTO; BTO:0002806
DR   CLO; CLO_0001544
DR   CLO; CLO_0001581
DR   CLO; CLO_0001582
DR   EFO; EFO_0002103
DR   MCCL; MCC:0000024
DR   CLDB; cl198
DR   CLDB; cl199
DR   Abcam; ab275461
DR   AddexBio; C0020004/4992
DR   ArrayExpress; E-MTAB-38
DR   ArrayExpress; E-MTAB-783
DR   ArrayExpress; E-MTAB-2706
DR   ArrayExpress; E-MTAB-2770
DR   ArrayExpress; E-MTAB-3610
DR   ATCC; CRL-1619
DR   ATCC; CRL-7904
DR   BCRC; 60039
DR   BCRJ; 0278
DR   BioGRID_ORCS_Cell_line; 44
DR   BioSample; SAMN03472142
DR   BioSample; SAMN05292441
DR   BioSample; SAMN07709998
DR   BioSample; SAMN07709999
DR   BioSample; SAMN07710000
DR   BioSample; SAMN07710001
DR   BioSample; SAMN07710002
DR   BioSample; SAMN07710003
DR   BioSample; SAMN07710004
DR   BioSample; SAMN10988347
DR   cancercelllines; CVCL_0132
DR   CCRID; 1101HUM-PUMC000126
DR   CCRID; 1101HUM-PUMC000327
DR   CCRID; 3101HUMTCHu155
DR   CCRID; 4201HUM-CCTCC00285
DR   Cell_Model_Passport; SIDM00795
DR   CGH-DB; 9313-4
DR   ChEMBL-Cells; CHEMBL3308077
DR   ChEMBL-Targets; CHEMBL613859
DR   CLS; 300110
DR   Cosmic; 686480
DR   Cosmic; 687431
DR   Cosmic; 706114
DR   Cosmic; 876698
DR   Cosmic; 888861
DR   Cosmic; 897482
DR   Cosmic; 897735
DR   Cosmic; 905226
DR   Cosmic; 906793
DR   Cosmic; 928688
DR   Cosmic; 933003
DR   Cosmic; 1006556
DR   Cosmic; 1022280
DR   Cosmic; 1054855
DR   Cosmic; 1132587
DR   Cosmic; 1155278
DR   Cosmic; 1211162
DR   Cosmic; 1303032
DR   Cosmic; 1458961
DR   Cosmic; 1459655
DR   Cosmic; 1477406
DR   Cosmic; 1481413
DR   Cosmic; 1507620
DR   Cosmic; 1537486
DR   Cosmic; 1555009
DR   Cosmic; 1669118
DR   Cosmic; 1812178
DR   Cosmic; 1888914
DR   Cosmic; 1890486
DR   Cosmic; 1989294
DR   Cosmic; 1995332
DR   Cosmic; 2036699
DR   Cosmic; 2230112
DR   Cosmic; 2233660
DR   Cosmic; 2479252
DR   Cosmic; 2791113
DR   Cosmic-CLP; 906793
DR   DepMap; ACH-000219
DR   ECACC; 88113005
DR   EGA; EGAS00001000610
DR   EGA; EGAS00001000978
DR   EGA; EGAS00001002554
DR   GDSC; 906793
DR   GEO; GSM206443
DR   GEO; GSM218051
DR   GEO; GSM274681
DR   GEO; GSM276771
DR   GEO; GSM555121
DR   GEO; GSM555173
DR   GEO; GSM827158
DR   GEO; GSM886854
DR   GEO; GSM887919
DR   GEO; GSM952580
DR   GEO; GSM1092559
DR   GEO; GSM1138787
DR   GEO; GSM1177892
DR   GEO; GSM1177893
DR   GEO; GSM1374382
DR   GEO; GSM1669582
DR   GEO; GSM1671962
DR   GEO; GSM1671967
DR   GEO; GSM1671977
DR   GEO; GSM1671981
DR   GEO; GSM1671982
DR   GEO; GSM1671987
DR   GEO; GSM1671990
DR   GEO; GSM1672001
DR   GEO; GSM1672004
DR   GEO; GSM1672007
DR   GEO; GSM1672011
DR   GEO; GSM1672017
DR   GEO; GSM1672024
DR   GEO; GSM1672027
DR   GEO; GSM1672030
DR   GEO; GSM1672039
DR   GEO; GSM1672051
DR   GEO; GSM1672062
DR   GEO; GSM1672067
DR   GEO; GSM1672078
DR   GEO; GSM1672097
DR   GEO; GSM1672102
DR   GEO; GSM1672119
DR   GEO; GSM1672135
DR   GEO; GSM3039510
DR   GEO; GSM3039516
DR   GEO; GSM3039517
DR   GEO; GSM3039518
DR   IARC_TP53; 21163
DR   IBRC; C10141
DR   IGRhCellID; A375
DR   KCB; KCB 99003YJ
DR   LiGeA; CCLE_226
DR   LINCS_HMS; 50060
DR   Lonza; 970
DR   NCBI_Iran; C136
DR   PharmacoDB; A375_42_2019
DR   PRIDE; PXD001485
DR   PRIDE; PXD004343
DR   PRIDE; PXD005912
DR   PRIDE; PXD007265
DR   PRIDE; PXD021877
DR   PRIDE; PXD022992
DR   PRIDE; PXD025255
DR   PRIDE; PXD025881
DR   PRIDE; PXD026952
DR   PRIDE; PXD027886
DR   PRIDE; PXD028863
DR   PRIDE; PXD030304
DR   Progenetix; CVCL_0132
DR   PubChem_Cell_line; CVCL_0132
DR   Ubigene; YC-C036
DR   Wikidata; Q54605986
RX   DOI=10.1007/BF00199208;
RX   DOI=10.1007/BF00205883;
RX   PubMed=77569;
RX   PubMed=327080;
RX   PubMed=375235;
RX   PubMed=833871;
RX   PubMed=1832891;
RX   PubMed=3518877;
RX   PubMed=4357758;
RX   PubMed=6220172;
RX   PubMed=6500159;
RX   PubMed=6584666;
RX   PubMed=6954533;
RX   PubMed=9670966;
RX   PubMed=9973934;
RX   PubMed=10497214;
RX   PubMed=12068308;
RX   PubMed=14871852;
RX   PubMed=15009714;
RX   PubMed=15467732;
RX   PubMed=17308088;
RX   PubMed=18172304;
RX   PubMed=19727395;
RX   PubMed=20164919;
RX   PubMed=20215515;
RX   PubMed=21343389;
RX   PubMed=21424129;
RX   PubMed=21673604;
RX   PubMed=21857157;
RX   PubMed=22178978;
RX   PubMed=22282976;
RX   PubMed=22460905;
RX   PubMed=23039341;
RX   PubMed=24581590;
RX   PubMed=25056119;
RX   PubMed=25485619;
RX   PubMed=25877200;
RX   PubMed=25960936;
RX   PubMed=26405815;
RX   PubMed=26589293;
RX   PubMed=26673621;
RX   PubMed=27397505;
RX   PubMed=28196595;
RX   PubMed=29275043;
RX   PubMed=29492214;
RX   PubMed=29605720;
RX   PubMed=30894373;
RX   PubMed=30971826;
RX   PubMed=31068700;
RX   PubMed=31978347;
RX   PubMed=35128241;
RX   PubMed=35839778;
CC   Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE).
CC   Part of: COSMIC cell lines project.
CC   Part of: MD Anderson Cell Lines Project.
CC   Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982).
CC   Population: Caucasian.
CC   Doubling time: 26.9 +- 6.9 hours (PubMed=29275043); ~32 hours (PBCF).
CC   HLA typing: A*01,02; B*12,13 (PubMed=77569).
CC   HLA typing: A*01:01,02:01; B*44:03,57:01; C*06:02,16:02; DQA1*03:02,02:01; DQB1*03:03,03:03; DRB1*04:05,07:01 (PubMed=25960936).
CC   HLA typing: A*01:01,02:01; B*44:03,57:01; C*06:02,16:01; DQA1*03:02,02:01; DQB1*03:02,03:02; DRB1*04:05,07:01 (PubMed=26589293).
CC   Microsatellite instability: Stable (MSS) (Sanger).
CC   Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Val600Glu (c.1799T>A); ClinVar=VCV000013961; Zygosity=Homozygous (PubMed=12068308; PubMed=15467732; PubMed=26405815; PubMed=29492214; ATCC=CRL-1619; Cosmic-CLP=906793; DepMap=ACH-000219).
CC   Sequence variation: Mutation; HGNC; 1787; CDKN2A; Simple; p.Glu61Ter (c.181G>T) (p.Gly75Val, c.224G>T); ClinVar=VCV000376309; Zygosity=Homozygous (PubMed=29492214; ATCC=CRL-1619; Cosmic-CLP=906793; DepMap=ACH-000219).
CC   Sequence variation: Mutation; HGNC; 1787; CDKN2A; Simple; p.Glu69Ter (c.205G>T) (p.Gly83Val, c.248G>T); ClinVar=VCV000376308; Zygosity=Homozygous (PubMed=29492214; ATCC=CRL-1619; Cosmic-CLP=906793; DepMap=ACH-000219).
CC   Sequence variation: Mutation; HGNC; 11730; TERT; Simple; c.1-146C>T (c.250C>T) (C250T); Zygosity=Unspecified; Note=In promoter (PubMed=31068700).
CC   Omics: Array-based CGH.
CC   Omics: CRISPR phenotypic screen.
CC   Omics: Deep exome analysis.
CC   Omics: Deep phosphoproteome analysis.
CC   Omics: Deep proteome analysis.
CC   Omics: Deep quantitative proteome analysis.
CC   Omics: DNA methylation analysis.
CC   Omics: Protein expression by reverse-phase protein arrays.
CC   Omics: Proteome analysis by 2D-DE/MS.
CC   Omics: Secretome proteome analysis.
CC   Omics: SNP array analysis.
CC   Omics: Transcriptome analysis by microarray.
CC   Omics: Transcriptome analysis by RNAseq.
CC   Genome ancestry: African=0.84%; Native American=0.49%; East Asian, North=1.69%; East Asian, South=0%; South Asian=0%; European, North=67.22%; European, South=29.75% (PubMed=30894373).
CC   Misspelling: A-735; Note=Occasionally.
CC   Discontinued: ATCC; CRL-7904; true.
CC   Derived from site: In situ; Skin; UBERON=UBERON_0002097.
ST   Source(s): AddexBio=C0020004/4992; ATCC=CRL-1619; CCRID; CLS=300110; Cosmic-CLP=906793; ECACC=88113005; Technion Genomics Center BCF; IZSLER=BS TCL 88; PubMed=25056119; PubMed=25877200
ST   Amelogenin: X
ST   CSF1PO: 11,12
ST   D10S1248: 16
ST   D12S391: 18,21
ST   D13S317: 11,14
ST   D16S539: 9
ST   D18S51: 12,17
ST   D19S433: 13,14.2
ST   D1S1656: 16,17.3
ST   D21S11: 29,30
ST   D22S1045: 16
ST   D2S1338: 16,24
ST   D2S441: 11
ST   D3S1358: 15,17
ST   D5S818: 12
ST   D7S820: 9
ST   D8S1179: 11,14
ST   FGA: 23
ST   Penta D: 9,15
ST   Penta E: 10,12
ST   TH01: 8
ST   TPOX: 8,10
ST   vWA: 16,17
DI   NCIt; C3802; Amelanotic melanoma
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
SX   Female
AG   54Y
CA   Cancer cell line
DT   Created: 04-04-12; Last updated: 02-05-24; Version: 46
RX   DOI=10.1007/BF00199208;
RA   Bruggen J., Sorg C., Macher E.;
RT   "Membrane associated antigens of human malignant melanoma V:
RT   Serological typing of cell lines using antisera from nonhuman
RT   primates.";
RL   Cancer Immunol. Immunother. 5:53-62(1978).
RX   DOI=10.1007/BF00205883;
RA   Bruggen J., Macher E., Sorg C.;
RT   "Expression of surface antigens and its relation to parameters of
RT   malignancy in human malignant melanoma.";
RL   Cancer Immunol. Immunother. 10:121-127(1981).
RX   PubMed=77569; DOI=10.1111/j.1399-0039.1978.tb01259.x;
RA   Espmark J.A., Ahlqvist-Roth L., Sarne L., Persson A.;
RT   "Tissue typing of cells in culture. III. HLA antigens of established
RT   human cell lines. Attempts at typing by the mixed hemadsorption
RT   technique.";
RL   Tissue Antigens 11:279-286(1978).
RX   PubMed=327080; DOI=10.1093/jnci/59.1.221;
RA   Fogh J., Fogh J.M., Orfeo T.;
RT   "One hundred and twenty-seven cultured human tumor cell lines
RT   producing tumors in nude mice.";
RL   J. Natl. Cancer Inst. 59:221-226(1977).
RX   PubMed=375235; DOI=10.1073/pnas.76.3.1288;
RA   Sherwin S.A., Sliski A.H., Todaro G.J.;
RT   "Human melanoma cells have both nerve growth factor and nerve growth
RT   factor-specific receptors on their cell surfaces.";
RL   Proc. Natl. Acad. Sci. U.S.A. 76:1288-1292(1979).
RX   PubMed=833871; DOI=10.1093/jnci/58.2.209;
RA   Fogh J., Wright W.C., Loveless J.D.;
RT   "Absence of HeLa cell contamination in 169 cell lines derived from
RT   human tumors.";
RL   J. Natl. Cancer Inst. 58:209-214(1977).
RX   PubMed=1832891; DOI=10.1016/0277-5379(91)90277-K;
RA   Hansson J., Fichtinger-Schepman A.M.J., Edgren M.R., Ringborg U.;
RT   "Comparative study of two human melanoma cell lines with different
RT   sensitivities to mustine and cisplatin.";
RL   Eur. J. Cancer 27:1039-1045(1991).
RX   PubMed=3518877; DOI=10.3109/07357908609038260;
RA   Fogh J.;
RT   "Human tumor lines for cancer research.";
RL   Cancer Invest. 4:157-184(1986).
RX   PubMed=4357758; DOI=10.1093/jnci/51.5.1417;
RA   Giard D.J., Aaronson S.A., Todaro G.J., Arnstein P., Kersey J.H.,
RA   Dosik H., Parks W.P.;
RT   "In vitro cultivation of human tumors: establishment of cell lines
RT   derived from a series of solid tumors.";
RL   J. Natl. Cancer Inst. 51:1417-1423(1973).
RX   PubMed=6220172;
RA   Dracopoli N.C., Fogh J.;
RT   "Polymorphic enzyme analysis of cultured human tumor cell lines.";
RL   J. Natl. Cancer Inst. 70:469-476(1983).
RX   PubMed=6500159; DOI=10.1159/000163283;
RA   Gershwin M.E., Lentz D., Owens R.B.;
RT   "Relationship between karyotype of tissue culture lines and
RT   tumorigenicity in nude mice.";
RL   Exp. Cell Biol. 52:361-370(1984).
RX   PubMed=6584666; DOI=10.1093/jnci/72.4.913;
RA   Kozlowski J.M., Hart I.R., Fidler I.J., Hanna N.;
RT   "A human melanoma line heterogeneous with respect to metastatic
RT   capacity in athymic nude mice.";
RL   J. Natl. Cancer Inst. 72:913-917(1984).
RX   PubMed=6954533; DOI=10.1073/pnas.79.7.2194;
RA   Westin E.H., Gallo R.C., Arya S.K., Eva A., Souza L.M., Baluda M.A.,
RA   Aaronson S.A., Wong-Staal F.;
RT   "Differential expression of the amv gene in human hematopoietic
RT   cells.";
RL   Proc. Natl. Acad. Sci. U.S.A. 79:2194-2198(1982).
RX   PubMed=9670966; DOI=10.4049/jimmunol.161.2.877;
RA   Bettinotti M.P., Kim C.J., Lee K.-H., Roden M., Cormier J.N.,
RA   Panelli M.C., Parker K.K., Marincola F.M.;
RT   "Stringent allele/epitope requirements for MART-1/Melan A
RT   immunodominance: implications for peptide-based immunotherapy.";
RL   J. Immunol. 161:877-889(1998).
RX   PubMed=9973934; DOI=10.1016/S0165-4608(98)00122-8;
RA   Nelson M.A., Ariza M.E., Yang J.-M., Thompson F.H., Taetle R.,
RA   Trent J.M., Wymer J., Massey-Brown K.S., Broome-Powell M., Easton J.,
RA   Lahti J.M., Kidd V.J.;
RT   "Abnormalities in the p34cdc2-related PITSLRE protein kinase gene
RT   complex (CDC2L) on chromosome band 1p36 in melanoma.";
RL   Cancer Genet. Cytogenet. 108:91-99(1999).
RX   PubMed=10497214; DOI=10.1074/jbc.274.40.28505;
RA   Ariza M.E., Broome-Powell M., Lahti J.M., Kidd V.J., Nelson M.A.;
RT   "Fas-induced apoptosis in human malignant melanoma cell lines is
RT   associated with the activation of the p34(cdc2)-related PITSLRE
RT   protein kinases.";
RL   J. Biol. Chem. 274:28505-28513(1999).
RX   PubMed=12068308; DOI=10.1038/nature00766;
RA   Davies H., Bignell G.R., Cox C., Stephens P.J., Edkins S., Clegg S.,
RA   Teague J.W., Woffendin H., Garnett M.J., Bottomley W., Davis N.,
RA   Dicks E., Ewing R., Floyd Y., Gray K., Hall S., Hawes R., Hughes J.,
RA   Kosmidou V., Menzies A., Mould C., Parker A., Stevens C., Watt S.,
RA   Hooper S., Wilson R., Jayatilake H., Gusterson B.A., Cooper C.S.,
RA   Shipley J.M., Hargrave D., Pritchard-Jones K., Maitland N.J.,
RA   Chenevix-Trench G., Riggins G.J., Bigner D.D., Palmieri G., Cossu A.,
RA   Flanagan A.M., Nicholson A., Ho J.W.C., Leung S.Y., Yuen S.T.,
RA   Weber B.L., Seigler H.F., Darrow T.L., Paterson H.F., Marais R.,
RA   Marshall C.J., Wooster R., Stratton M.R., Futreal P.A.;
RT   "Mutations of the BRAF gene in human cancer.";
RL   Nature 417:949-954(2002).
RX   PubMed=14871852; DOI=10.1158/0008-5472.CAN-03-2209;
RA   Hogan K.T., Coppola M.A., Gatlin C.L., Thompson L.W., Shabanowitz J.,
RA   Hunt D.F., Engelhard V.H., Ross M.M., Slingluff C.L. Jr.;
RT   "Identification of novel and widely expressed cancer/testis gene
RT   isoforms that elicit spontaneous cytotoxic T-lymphocyte reactivity to
RT   melanoma.";
RL   Cancer Res. 64:1157-1163(2004).
RX   PubMed=15009714; DOI=10.1046/j.0022-202X.2004.22243.x;
RA   Tsao H., Goel V., Wu H., Yang G., Haluska F.G.;
RT   "Genetic interaction between NRAS and BRAF mutations and PTEN/MMAC1
RT   inactivation in melanoma.";
RL   J. Invest. Dermatol. 122:337-341(2004).
RX   PubMed=15467732; DOI=10.1038/sj.onc.1208152;
RA   Tanami H., Imoto I., Hirasawa A., Yuki Y., Sonoda I., Inoue J.,
RA   Yasui K., Misawa-Furihata A., Kawakami Y., Inazawa J.;
RT   "Involvement of overexpressed wild-type BRAF in the growth of
RT   malignant melanoma cell lines.";
RL   Oncogene 23:8796-8804(2004).
RX   PubMed=17308088; DOI=10.1158/0008-5472.CAN-06-3311;
RA   Shields J.M., Thomas N.E., Cregger M., Berger A.J., Leslie M.,
RA   Torrice C., Hao H.-L., Penland S., Arbiser J.L., Scott G.A., Zhou T.,
RA   Bar-Eli M., Bear J.E., Der C.J., Kaufmann W.K., Rimm D.L.,
RA   Sharpless N.E.;
RT   "Lack of extracellular signal-regulated kinase mitogen-activated
RT   protein kinase signaling shows a new type of melanoma.";
RL   Cancer Res. 67:1502-1512(2007).
RX   PubMed=18172304; DOI=10.1158/0008-5472.CAN-07-1939;
RA   Sabatino M., Zhao Y.-D., Voiculescu S., Monaco A., Robbins P.F.,
RA   Karai L., Nickoloff B.J., Maio M., Selleri S., Marincola F.M., Wang E.;
RT   "Conservation of genetic alterations in recurrent melanoma supports
RT   the melanoma stem cell hypothesis.";
RL   Cancer Res. 68:122-131(2008).
RX   PubMed=19727395; DOI=10.1371/journal.pone.0006888;
RA   Wadlow R.C., Wittner B.S., Finley S.A., Bergquist H., Upadhyay R.,
RA   Finn S.P., Loda M., Mahmood U., Ramaswamy S.;
RT   "Systems-level modeling of cancer-fibroblast interaction.";
RL   PLoS ONE 4:E6888-E6888(2009).
RX   PubMed=20164919; DOI=10.1038/nature08768;
RA   Bignell G.R., Greenman C.D., Davies H., Butler A.P., Edkins S.,
RA   Andrews J.M., Buck G., Chen L., Beare D., Latimer C., Widaa S.,
RA   Hinton J., Fahey C., Fu B.-Y., Swamy S., Dalgliesh G.L., Teh B.T.,
RA   Deloukas P., Yang F.-T., Campbell P.J., Futreal P.A., Stratton M.R.;
RT   "Signatures of mutation and selection in the cancer genome.";
RL   Nature 463:893-898(2010).
RX   PubMed=20215515; DOI=10.1158/0008-5472.CAN-09-3458;
RA   Rothenberg S.M., Mohapatra G., Rivera M.N., Winokur D., Greninger P.,
RA   Nitta M., Sadow P.M., Sooriyakumar G., Brannigan B.W., Ulman M.J.,
RA   Perera R.M., Wang R., Tam A., Ma X.-J., Erlander M., Sgroi D.C.,
RA   Rocco J.W., Lingen M.W., Cohen E.E.W., Louis D.N., Settleman J.,
RA   Haber D.A.;
RT   "A genome-wide screen for microdeletions reveals disruption of
RT   polarity complex genes in diverse human cancers.";
RL   Cancer Res. 70:2158-2164(2010).
RX   PubMed=21343389; DOI=10.1158/0008-5472.CAN-10-2958;
RA   Rose A.E., Poliseno L., Wang J.-H., Clark M., Pearlman A., Wang G.-M.,
RA   Vega y Saenz de Miera E.C., Medicherla R., Christos P.J., Shapiro R.,
RA   Pavlick A., Darvishian F., Zavadil J., Polsky D., Hernando E.,
RA   Ostrer H., Osman I.;
RT   "Integrative genomics identifies molecular alterations that challenge
RT   the linear model of melanoma progression.";
RL   Cancer Res. 71:2561-2571(2011).
RX   PubMed=21424129; DOI=10.3892/or.2011.1220;
RA   Manca A., Sini M.C., Izzo F., Ascierto P.A., Tatangelo F., Botti G.,
RA   Gentilcore G., Capone M., Mozzillo N., Rozzo C., Cossu A., Tanda F.,
RA   Palmieri G.;
RT   "Induction of arginosuccinate synthetase (ASS) expression affects the
RT   antiproliferative activity of arginine deiminase (ADI) in melanoma
RT   cells.";
RL   Oncol. Rep. 25:1495-1502(2011).
RX   PubMed=21673604; DOI=10.1097/CMR.0b013e32834495c3;
RA   Orgaz J.L., Benguria A., Sanchez-Martinez C., Ladhani O.,
RA   Volpert O.V., Jimenez B.;
RT   "Changes in the gene expression profile of A375 human melanoma cells
RT   induced by overexpression of multifunctional pigment
RT   epithelium-derived factor.";
RL   Melanoma Res. 21:285-297(2011).
RX   PubMed=21857157; DOI=10.4161/cc.10.17.17068;
RA   Caputo E., Maiorana L., Vasta V., Pezzino F.M., Sunkara S., Wynne K.,
RA   Elia G., Marincola F.M., McCubrey J.A., Libra M., Travali S., Kane M.;
RT   "Characterization of human melanoma cell lines and melanocytes by
RT   proteome analysis.";
RL   Cell Cycle 10:2924-2936(2011).
RX   PubMed=22178978; DOI=10.1016/j.freeradbiomed.2011.11.019;
RA   Swalwell H., Latimer J., Haywood R.M., Birch-Machin M.A.;
RT   "Investigating the role of melanin in UVA/UVB- and hydrogen
RT   peroxide-induced cellular and mitochondrial ROS production and
RT   mitochondrial DNA damage in human melanoma cells.";
RL   Free Radic. Biol. Med. 52:626-634(2012).
RX   PubMed=22282976; DOI=10.1093/carcin/1.1.21;
RA   Day R.S. III, Ziolkowski C.H.J., Scudiero D.A., Meyer S.A.,
RA   Mattern M.R.;
RT   "Human tumor cell strains defective in the repair of alkylation
RT   damage.";
RL   Carcinogenesis 1:21-32(1980).
RX   PubMed=22460905; DOI=10.1038/nature11003;
RA   Barretina J.G., Caponigro G., Stransky N., Venkatesan K., Margolin A.A.,
RA   Kim S., Wilson C.J., Lehar J., Kryukov G.V., Sonkin D., Reddy A.,
RA   Liu M., Murray L., Berger M.F., Monahan J.E., Morais P., Meltzer J.,
RA   Korejwa A., Jane-Valbuena J., Mapa F.A., Thibault J., Bric-Furlong E.,
RA   Raman P., Shipway A., Engels I.H., Cheng J., Yu G.-Y.K., Yu J.-J.,
RA   Aspesi P. Jr., de Silva M., Jagtap K., Jones M.D., Wang L., Hatton C.,
RA   Palescandolo E., Gupta S., Mahan S., Sougnez C., Onofrio R.C.,
RA   Liefeld T., MacConaill L.E., Winckler W., Reich M., Li N.-X., Mesirov J.P.,
RA   Gabriel S.B., Getz G., Ardlie K., Chan V., Myer V.E., Weber B.L.,
RA   Porter J., Warmuth M., Finan P., Harris J.L., Meyerson M.L., Golub T.R.,
RA   Morrissey M.P., Sellers W.R., Schlegel R., Garraway L.A.;
RT   "The Cancer Cell Line Encyclopedia enables predictive modelling of
RT   anticancer drug sensitivity.";
RL   Nature 483:603-607(2012).
RX   PubMed=23039341; DOI=10.1186/1476-4598-11-75;
RA   Byron S.A., Loch D.C., Wellens C.L., Wortmann A., Wu J.-Y., Wang J.,
RA   Nomoto K., Pollock P.M.;
RT   "Sensitivity to the MEK inhibitor E6201 in melanoma cells is
RT   associated with mutant BRAF and wildtype PTEN status.";
RL   Mol. Cancer 11:75.1-75.15(2012).
RX   PubMed=24581590; DOI=10.1016/j.jdermsci.2014.01.006;
RA   Gehrke S., Otsuka A., Huber R., Meier B., Kistowska M., Fenini G.,
RA   Cheng P., Dummer R., Kerl K., Contassot E., French L.E.;
RT   "Metastatic melanoma cell lines do not secrete IL-1beta but promote
RT   IL-1beta production from macrophages.";
RL   J. Dermatol. Sci. 74:167-169(2014).
RX   PubMed=25056119; DOI=10.1158/0008-5472.CAN-14-1232-T;
RA   Watson I.R., Li L.-R., Cabeceiras P.K., Mahdavi M., Gutschner T.,
RA   Genovese G., Wang G.-C., Fang Z.-N., Tepper J.M., Stemke-Hale K., Tsai K.Y.,
RA   Davies M.A., Mills G.B., Chin L.;
RT   "The RAC1 P29S hotspot mutation in melanoma confers resistance to
RT   pharmacological inhibition of RAF.";
RL   Cancer Res. 74:4845-4852(2014).
RX   PubMed=25485619; DOI=10.1038/nbt.3080;
RA   Klijn C., Durinck S., Stawiski E.W., Haverty P.M., Jiang Z.-S.,
RA   Liu H.-B., Degenhardt J., Mayba O., Gnad F., Liu J.-F., Pau G.,
RA   Reeder J., Cao Y., Mukhyala K., Selvaraj S.K., Yu M.-M., Zynda G.J.,
RA   Brauer M.J., Wu T.D., Gentleman R.C., Manning G., Yauch R.L.,
RA   Bourgon R., Stokoe D., Modrusan Z., Neve R.M., de Sauvage F.J.,
RA   Settleman J., Seshagiri S., Zhang Z.-M.;
RT   "A comprehensive transcriptional portrait of human cancer cell
RT   lines.";
RL   Nat. Biotechnol. 33:306-312(2015).
RX   PubMed=25877200; DOI=10.1038/nature14397;
RA   Yu M., Selvaraj S.K., Liang-Chu M.M.Y., Aghajani S., Busse M.,
RA   Yuan J., Lee G., Peale F.V., Klijn C., Bourgon R., Kaminker J.S.,
RA   Neve R.M.;
RT   "A resource for cell line authentication, annotation and quality
RT   control.";
RL   Nature 520:307-311(2015).
RX   PubMed=25960936; DOI=10.4161/21624011.2014.954893;
RA   Boegel S., Lower M., Bukur T., Sahin U., Castle J.C.;
RT   "A catalog of HLA type, HLA expression, and neo-epitope candidates in
RT   human cancer cell lines.";
RL   OncoImmunology 3:e954893.1-e954893.12(2014).
RX   PubMed=26405815; DOI=10.1371/journal.pone.0138210;
RA   Capaldo B.J., Roller D.G., Axelrod M.J., Koeppel A.F., Petricoin E.F. III,
RA   Slingluff C.L. Jr., Weber M.J., Mackey A.J., Gioeli D., Bekiranov S.;
RT   "Systems analysis of adaptive responses to MAP kinase pathway blockade
RT   in BRAF mutant melanoma.";
RL   PLoS ONE 10:E0138210-E0138210(2015).
RX   PubMed=26589293; DOI=10.1186/s13073-015-0240-5;
RA   Scholtalbers J., Boegel S., Bukur T., Byl M., Goerges S., Sorn P.,
RA   Loewer M., Sahin U., Castle J.C.;
RT   "TCLP: an online cancer cell line catalogue integrating HLA type,
RT   predicted neo-epitopes, virus and gene expression.";
RL   Genome Med. 7:118.1-118.7(2015).
RX   PubMed=26673621; DOI=10.18632/oncotarget.6548;
RA   Roller D.G., Capaldo B.J., Bekiranov S., Mackey A.J., Conaway M.R.,
RA   Petricoin E.F. III, Gioeli D., Weber M.J.;
RT   "Combinatorial drug screening and molecular profiling reveal diverse
RT   mechanisms of intrinsic and adaptive resistance to BRAF inhibition in
RT   V600E BRAF mutant melanomas.";
RL   Oncotarget 7:2734-2753(2016).
RX   PubMed=27397505; DOI=10.1016/j.cell.2016.06.017;
RA   Iorio F., Knijnenburg T.A., Vis D.J., Bignell G.R., Menden M.P.,
RA   Schubert M., Aben N., Goncalves E., Barthorpe S., Lightfoot H.,
RA   Cokelaer T., Greninger P., van Dyk E., Chang H., de Silva H., Heyn H.,
RA   Deng X.-M., Egan R.K., Liu Q.-S., Mironenko T., Mitropoulos X.,
RA   Richardson L., Wang J.-H., Zhang T.-H., Moran S., Sayols S.,
RA   Soleimani M., Tamborero D., Lopez-Bigas N., Ross-Macdonald P.,
RA   Esteller M., Gray N.S., Haber D.A., Stratton M.R., Benes C.H.,
RA   Wessels L.F.A., Saez-Rodriguez J., McDermott U., Garnett M.J.;
RT   "A landscape of pharmacogenomic interactions in cancer.";
RL   Cell 166:740-754(2016).
RX   PubMed=28196595; DOI=10.1016/j.ccell.2017.01.005;
RA   Li J., Zhao W., Akbani R., Liu W.-B., Ju Z.-L., Ling S.-Y., Vellano C.P.,
RA   Roebuck P., Yu Q.-H., Eterovic A.K., Byers L.A., Davies M.A., Deng W.-L.,
RA   Gopal Y.N.V., Chen G., von Euw E.M., Slamon D.J., Conklin D.,
RA   Heymach J.V., Gazdar A.F., Minna J.D., Myers J.N., Lu Y.-L., Mills G.B.,
RA   Liang H.;
RT   "Characterization of human cancer cell lines by reverse-phase protein
RT   arrays.";
RL   Cancer Cell 31:225-239(2017).
RX   PubMed=29275043; DOI=10.1016/j.jprot.2017.12.013;
RA   Liberato T., Pessotti D.S., Fukushima I., Kitano E.S., Serrano S.M.T.,
RA   Zelanis A.;
RT   "Signatures of protein expression revealed by secretome analyses of
RT   cancer associated fibroblasts and melanoma cell lines.";
RL   J. Proteomics 174:1-8(2018).
RX   PubMed=29492214; DOI=10.18632/oncotarget.23989;
RA   Sini M.C., Doneddu V., Paliogiannis P., Casula M., Colombino M.,
RA   Manca A., Botti G., Ascierto P.A., Lissia A., Cossu A., Palmieri G.;
RT   "Genetic alterations in main candidate genes during melanoma
RT   progression.";
RL   Oncotarget 9:8531-8541(2018).
RX   PubMed=29605720; DOI=10.1016/j.neo.2018.02.009;
RA   Mologni L., Costanza M., Sharma G.G., Viltadi M., Massimino L.,
RA   Citterio S., Purgante S., Raman H., Pirola A., Zucchetti M.,
RA   Piazza R., Gambacorti-Passerini C.;
RT   "Concomitant BCORL1 and BRAF mutations in vemurafenib-resistant
RT   melanoma cells.";
RL   Neoplasia 20:467-477(2018).
RX   PubMed=30894373; DOI=10.1158/0008-5472.CAN-18-2747;
RA   Dutil J., Chen Z.-H., Monteiro A.N.A., Teer J.K., Eschrich S.A.;
RT   "An interactive resource to probe genetic diversity and estimated
RT   ancestry in cancer cell lines.";
RL   Cancer Res. 79:1263-1273(2019).
RX   PubMed=30971826; DOI=10.1038/s41586-019-1103-9;
RA   Behan F.M., Iorio F., Picco G., Goncalves E., Beaver C.M.,
RA   Migliardi G., Santos R., Rao Y., Sassi F., Pinnelli M., Ansari R.,
RA   Harper S., Jackson D.A., McRae R., Pooley R., Wilkinson P.,
RA   van der Meer D.J., Dow D., Buser-Doepner C.A., Bertotti A., Trusolino L.,
RA   Stronach E.A., Saez-Rodriguez J., Yusa K., Garnett M.J.;
RT   "Prioritization of cancer therapeutic targets using CRISPR-Cas9
RT   screens.";
RL   Nature 568:511-516(2019).
RX   PubMed=31068700; DOI=10.1038/s41586-019-1186-3;
RA   Ghandi M., Huang F.W., Jane-Valbuena J., Kryukov G.V., Lo C.C.,
RA   McDonald E.R. III, Barretina J.G., Gelfand E.T., Bielski C.M., Li H.-X.,
RA   Hu K., Andreev-Drakhlin A.Y., Kim J., Hess J.M., Haas B.J., Aguet F.,
RA   Weir B.A., Rothberg M.V., Paolella B.R., Lawrence M.S., Akbani R.,
RA   Lu Y.-L., Tiv H.L., Gokhale P.C., de Weck A., Mansour A.A., Oh C.,
RA   Shih J., Hadi K., Rosen Y., Bistline J., Venkatesan K., Reddy A.,
RA   Sonkin D., Liu M., Lehar J., Korn J.M., Porter D.A., Jones M.D.,
RA   Golji J., Caponigro G., Taylor J.E., Dunning C.M., Creech A.L.,
RA   Warren A.C., McFarland J.M., Zamanighomi M., Kauffmann A.,
RA   Stransky N., Imielinski M., Maruvka Y.E., Cherniack A.D.,
RA   Tsherniak A., Vazquez F., Jaffe J.D., Lane A.A., Weinstock D.M.,
RA   Johannessen C.M., Morrissey M.P., Stegmeier F., Schlegel R.,
RA   Hahn W.C., Getz G., Mills G.B., Boehm J.S., Golub T.R., Garraway L.A.,
RA   Sellers W.R.;
RT   "Next-generation characterization of the Cancer Cell Line
RT   Encyclopedia.";
RL   Nature 569:503-508(2019).
RX   PubMed=31978347; DOI=10.1016/j.cell.2019.12.023;
RA   Nusinow D.P., Szpyt J., Ghandi M., Rose C.M., McDonald E.R. III,
RA   Kalocsay M., Jane-Valbuena J., Gelfand E.T., Schweppe D.K.,
RA   Jedrychowski M.P., Golji J., Porter D.A., Rejtar T., Wang Y.K.,
RA   Kryukov G.V., Stegmeier F., Erickson B.K., Garraway L.A.,
RA   Sellers W.R., Gygi S.P.;
RT   "Quantitative proteomics of the Cancer Cell Line Encyclopedia.";
RL   Cell 180:387-402.e16(2020).
RX   PubMed=35128241; DOI=10.1021/acsomega.1c05361;
RA   Martinez R. III, Huang W.-L., Buck H., Rea S., Defnet A.E., Kane M.A.,
RA   Shapiro P.;
RT   "Proteomic changes in the monolayer and spheroid melanoma cell models
RT   of acquired resistance to BRAF and MEK1/2 inhibitors.";
RL   ACS Omega 7:3293-3311(2022).
RX   PubMed=35839778; DOI=10.1016/j.ccell.2022.06.010;
RA   Goncalves E., Poulos R.C., Cai Z.-X., Barthorpe S., Manda S.S., Lucas N.,
RA   Beck A., Bucio-Noble D., Dausmann M., Hall C., Hecker M., Koh J.,
RA   Lightfoot H., Mahboob S., Mali I., Morris J., Richardson L.,
RA   Seneviratne A.J., Shepherd R., Sykes E., Thomas F., Valentini S.,
RA   Williams S.G., Wu Y.-X., Xavier D., MacKenzie K.L., Hains P.G., Tully B.,
RA   Robinson P.J., Zhong Q., Garnett M.J., Reddel R.R.;
RT   "Pan-cancer proteomic map of 949 human cell lines.";
RL   Cancer Cell 40:835-849.e8(2022).